I have followed IPF for more years than I care to mention.
Over that time I have seen so many holes and bumps (not called idiopathic for nothing) in the development path that I was not willing to credit FGEN with getting it right.
So the recent data on pamrevlumab derisked that program and added the potential that they have a more general anti-fibrotic drug with significant upside in multiple indications. The issue that raises is that the company is not prepared to do the development of the broader scope. A BIG RICH partner is needed. (GILD???)
Thus, I added shares of FGEN. I do affirm mcbio's view that either rox or pam can easily justify the value of buying FGEN here.
Market Data 
Markets 
AI
